Marianne Baastrup Soendergaard

Marianne Baastrup Soendergaard

Auto-generated profile, based on publicly available information

Marianne Baastrup Soendergaard

Dept of Respiratory Medicine, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CWChristian Woehlk
Christian Woehlk
ABAnna Von Bülow
Anna Von Bülow
MGMuzhda Ghanizada
Muzhda Ghanizada
MSMarianne Baastrup Søndergaard
Marianne Baastrup Søndergaard
SHSusanne Hansen
Susanne Hansen
CPCeleste Porsbjerg
Celeste Porsbjerg
Background: Allergic asthma is associated with increased risk of respiratory tract infections and exacerbations. It remains unclear whether this susceptibility is conditioned by seasonal or by perennial allergy.Aim: To investigate perennial allergy compared with seasonal allergy as a risk factor for lower respiratory tract infections and exacerbations in asthma and whether this risk can be reduced by allergen immunotherapy (AIT).Methodology: This is a prospective register-based nationwide study of 18–44-year-olds treated with AIT during 1995–2014. Based on the type of AIT and use of anti-asthmatic drugs, patients were subdivided into two groups: perennial allergic asthma (PAA)versusseasonal allergic asthma (SAA). Data on antibiotics against lower respiratory tract infections (LRTI) and oral corticosteroids for exacerbations were analysed before starting AIT (baseline) and 3 years after completing AIT (follow-up).Results: We identified 2688 patients with asthma treated with AIT, of whom 1249 had PAA and 1439 had SAA. At baseline, patients with SAA had more exacerbations (23.8%versus16.5%, p≤0.001), but there were no differences in LRTI. During the 3-year follow-up, we observed a highly significant reduction of exacerbations with an average decrease of 57% in PAA and 74% in SAA. In addition, we observed a significant reduction of LRTI in both PAA and SAA: 17% and 20% decrease, respectively.Conclusion: AIT effectively reduced the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma. Perennial allergy is seemingly not a stronger risk factor for respiratory infections and exacerbations than seasonal allergy.

4 October 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
SHSusanne Hansen
Susanne Hansen
ABAnne-Sofie Bjerrum
Anne-Sofie Bjerrum
OHOle Hilberg
Ole Hilberg
SLSofie Lock-Johansson
Sofie Lock-Johansson
CPCeleste Porsbjerg
Celeste Porsbjerg
Background: Phase III regulatory trials show that anti-interleukin (IL)-5 biologics efficiently reduce exacerbations and the use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligible for these trials differ significantly compared with real-life severe asthma populations. Therefore, our aim was to explore efficacy in a real-life setting. The Danish Severe Asthma Register (DSAR) is a complete, nationwide register that comprises all Danish patients on biological therapy for severe asthma.Methods: This prospective study identified patients in the DSAR who were complete responders to anti-IL-5 biologics after 1 year of treatment. A complete response was defined as resolution of the parameter setting the indication,i.e.recurrent exacerbations and/or use of mOCS.Results: A total of 289 out of 502 (58%) patients were complete responders to anti-IL-5 biologics after 12 months. Complete responders had greater improvements in forced expiratory volume in 1 s and Asthma Control Questionnaire (ACQ) score compared with noncomplete responders (Δ 210versus30 mL; p<0.0001 and Δ −1.04versus−0.68; p=0.016, respectively). A complete response was predicted by age at onset, less severe disease at baseline (i.e.no mOCS and lower ACQ score) and higher blood eosinophils.Conclusions: More than half of Danish patients treated with anti-IL-5 biologics for severe asthma achieve a complete response to treatment, thereby becoming free from asthma exacerbations and the need for mOCS. Complete responders also achieved superior effects on lung function and symptoms compared with noncomplete responders.

6 June 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
ABAnne-Sofie Bjerrum
Anne-Sofie Bjerrum
LRLinda Makowska Rasmussen
Linda Makowska Rasmussen
SLSofie Lock-Johansson
Sofie Lock-Johansson
OHOle Hilberg
Ole Hilberg
CPCeleste Porsbjerg
Celeste Porsbjerg
Background: Anti-interleukin (IL)-5 biologics effectively reduce exacerbations and the need for maintenance oral corticosteroids (mOCS) in severe eosinophilic asthma. However, it is unknown how long anti-IL-5 treatment should be continued. Data from clinical trials indicate a gradual but variable loss of control after treatment cessation. In this pilot study of titration, we evaluated a dose-titration algorithm in patients who had achieved clinical control on an anti-IL-5 biologic.Methods: In this open-label randomised controlled trial conducted over 52 weeks, patients with clinical control (no exacerbations or mOCS) on anti-IL-5 treatment were randomised to continue with unchanged intervals or have dosing intervals adjusted according to a titration algorithm that gradually extended dosing intervals and reduced them again at signs of loss of disease control. The OPTIMAL algorithm was designed to down-titrate dosing until signs of loss of control, to enable assessment of the longest dosing interval possible.Results: Among 73 patients enrolled, 37 patients were randomised to the OPTIMAL titration arm; 78% of patients tolerated down-titration of treatment. Compared to the control arm, the OPTIMAL arm tended to have more exacerbations during the study (32%versus17%; p=0.13). There were no severe adverse events related to titration, and lung function and symptoms scores remained stable and comparable in both study arms throughout.Conclusion: This study serves as a proof of concept for titration of anti-IL-5 biologics in patients with severe asthma with clinical control on treatment, and the OPTIMAL algorithm provides a potential framework for individualising dosing intervals in the future.

9 January 2025 in European Respiratory Journal
Verified
Journal Article
Open access
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
FHFrederikke Hjortdahl
Frederikke Hjortdahl
SHSusanne Hansen
Susanne Hansen
ABAnne-Sofie Bjerrum
Anne-Sofie Bjerrum
ABAnna von Bülow
Anna von Bülow
KHKjell Erik Julius Håkansson
Kjell Erik Julius Håkansson
Background: Biologics can induce remission in some patients with severe asthma; however, little is known about pre-biologic disease trajectories and their association with outcomes from biological treatment. We aimed to identify long-term trajectories of disease progression in patients initiating biologics and investigate trajectory associations with disease burden and impact on biologic therapy efficacy.Methods: Patients in the Danish Severe Asthma Register initiating biologic therapy between 2016 and 2022 were included and followed retrospectively in prescription databases starting 1995. We performed sequence analysis for inhaled corticosteroid treatment intensity over time combined with unsupervised trajectory clustering.Results: In total, 755 patients were included and three pre-biologic disease trajectories were identified: “Chronic severe asthma” (26%), “Gradual onset severe asthma” (35%) and “Recent, sudden onset severe asthma” (39%). “Chronic severe asthma” patients were older, had the longest disease duration (35 years), the most impaired pulmonary function, the highest comorbidity prevalence and the lowest employment rate. “Recent, sudden onset severe asthma” patients were younger, had shorter disease duration (5 years), more tobacco exposure and the least impaired lung function. “Gradual onset severe asthma” patients had an intermediate burden of disease. The“Chronic severe asthma” cluster demonstrated the lowest prevalence of remission (17%) compared to the “Gradual onset severe asthma” (29%) and “Recent, sudden onset severe asthma” (32%) clusters.Conclusions: Three pre-biologic disease trajectories were identified, with increased disease duration and activity associating with asthma and comorbidity burden. Early intervention may be key to prevent irreversible adverse outcomes for patients with severe asthma.

11 October 2023 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
SHSusanne Hansen
Susanne Hansen
ABAnne-Sofie Bjerrum
Anne-Sofie Bjerrum
ABAnna von Bülow
Anna von Bülow
KHKjell Erik Julius Haakansson
Kjell Erik Julius Haakansson
CPCeleste Porsbjerg
Celeste Porsbjerg
Randomized trials of biologics in severe, uncontrolled asthma have excluded patients with a cumulative tobacco exposure of more than 10 pack years. Therefore, our knowledge of the impact of smoking exposure on the clinical effects of biologics in severe asthma remains incomplete. However, since many patients with asthma are current or former smokers, investigating the potential impacts of tobacco exposure on the effects of biological treatment is clinically important. To investigate the impact of smoking history and tobacco exposure on the effectiveness of biologic therapy in real-life patients with severe asthma. We utilized data from a complete nationwide cohort of patients with severe asthma on biologics, the Danish Severe Asthma Register (DSAR). We divided patients according to smoking history and cumulative tobacco exposure and analysed data at baseline and after 12 months of biological treatment. A total of 724 bio-naive patients were identified in DSAR, of whom 398 (55%) were never smokers, 316 (44%) were previous smokers, and 10 (1%) were current smokers. Within the group of current and former smokers, 37% had 1-9 pack years of tobacco exposure, 26% had 10-19 pack years, and 37% had ≥20 pack years of tobacco exposure. Patients with tobacco exposure had similar reductions in the number of exacerbations, reductions in maintenance oral corticosteroid use, and improvements in asthma symptoms compared to patients with zero pack years. Former smoking history and lifetime tobacco exposure do not impact the efficacy of biologics in patients with severe asthma.

14 December 2024 in Allergy
Verified
Journal Article
Closed access
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
SHSusanne Hansen
Susanne Hansen
KHKjell Erik Julius Håkansson
Kjell Erik Julius Håkansson
ABAnna von Bülow
Anna von Bülow
ABAnne‐Sofie Bjerrum
Anne‐Sofie Bjerrum
CPCeleste Porsbjerg
Celeste Porsbjerg